SCHEMBL6844185

SCHEMBL6844185

C(#Cc1n[nH]c2ccc(-c3cnn[nH]3)cc12)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.40
MKNK1 Q9BUB5 1/20 0.37
AXL P30530 2/20 0.35
MAP4K4 O95819 2/20 0.33
CDK2 P24941 2/20 0.33
CLK2 P49760 2/20 0.33
DYRK1A Q13627 2/20 0.33
AURKB Q96GD4 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
MKNK2 Q9HBH9 2/20 0.33
IRAK4 Q9NWZ3 2/20 0.33
DCLK1 O15075 1/20 0.33
PRKD3 O94806 1/20 0.33
CHEK2 O96017 1/20 0.33
CSF1R P07333 1/20 0.33
FER P16591 1/20 0.33
MARK3 P27448 1/20 0.33
FLT4 P35916 1/20 0.33
FLT3 P36888 1/20 0.33
MAPK9 P45984 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5373114 0.78 JAK2 (0.40) JAK2MKNK1AXLMAP4K4CDK2
SCHEMBL14514439 0.77 JAK2 (0.39) JAK2MKNK1AXLMAP4K4CDK2
SCHEMBL5373142 0.75 JAK2 (0.41) JAK2MKNK1AXLMAP4K4CDK2
SCHEMBL4006815 0.74 MAPT (0.46) JAK2AXLMAP4K4CDK2CLK2
SCHEMBL5379524 0.74 MKNK1 (0.39) JAK2MKNK1AXLMAP4K4CDK2
SCHEMBL8253395 0.74 VCP (0.47) JAK2MKNK1
SCHEMBL5373162 0.73 ITK (0.50)
SCHEMBL7982776 0.73 KDM4E (0.48) CDK2FLT3TTKKDM4EALDH1A1
SCHEMBL5377963 0.69 GRM5 (0.47) JAK2CHEK2JAK1TTK
SCHEMBL7092069 0.67 PRKAG1 (0.48) MKNK1CLK2DYRK1ATTKGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK MAPK1, MAP3K1, MAPKAPK2 JAK2 123/4885MKNK1 66/4885AXL 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.